Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBITDA (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of EBITDA data on record, last reported at -$19.6 million in Q1 2026.

  • On a quarterly basis, EBITDA fell 10.52% to -$19.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$79.2 million, a 2548.95% decrease, with the full-year FY2025 number at -$74.8 million, down 691.16% from a year prior.
  • EBITDA reached -$19.6 million in Q1 2026 per FULC's latest filing, up from -$20.4 million in the prior quarter.
  • Over the last five years, EBITDA for FULC hit a ceiling of $52.5 million in Q2 2024 and a floor of -$34.0 million in Q2 2022.
  • A 5-year average of -$19.6 million and a median of -$24.4 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 292.33% in 2024, then tumbled 137.75% in 2025.
  • Tracing FULC's EBITDA over 5 years: stood at -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then skyrocketed by 39.92% to -$16.8 million in 2024, then fell by 21.31% to -$20.4 million in 2025, then increased by 4.03% to -$19.6 million in 2026.
  • Business Quant data shows EBITDA for FULC at -$19.6 million in Q1 2026, -$20.4 million in Q4 2025, and -$19.4 million in Q3 2025.